MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2025. Recent Highlights Total revenue for the fourth quarter 2025 was $16.0 million, an increase of 4% over the prior year quarterU.S. revenue for the fourth ...

Core Viewpoint - CVRx, Inc. is set to release its fourth quarter 2025 financial and operating results on February 12, 2026, after market close, followed by a conference call to discuss the results [1]. Company Overview - CVRx, Inc. is a commercial-stage medical device company that specializes in developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3]. - The company's flagship product, Barostim™, is the first FDA-approved medical technology that utilizes neuromodulation to alleviate symptoms in heart failure patients [3]. - Barostim is an implantable device that sends electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3]. - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation (MDR) and holding CE Mark for heart failure and resistant hypertension in the European Economic Area [3].

Core Insights - CVRx, Inc. reported preliminary unaudited revenue results for Q4 and full year 2025, indicating growth and strategic progress in the commercialization of its neuromodulation solutions for cardiovascular diseases [1][2][18] Financial Performance - Q4 2025 revenue is expected to be between $15.9 million and $16.1 million, reflecting a growth of approximately 4% to 5% compared to Q4 2024 revenue of $15.3 million [3][8] - Full year 2025 revenue is projected to be between $56.5 million and $56.7 million, representing an increase of approximately 10% to 11% over 2024 revenue of $51.3 million [4][8] - For Q1 2026, the company anticipates total revenue between $13.7 million and $14.7 million [6] Business Outlook - The company expects full year 2026 revenue to be between $63 million and $67 million, indicating growth of 11% to 18% [8] - The transition to Category I CPT codes effective January 1, 2026, is expected to enhance reimbursement dynamics and support commercial efforts [2][8] Operational Highlights - As of December 31, 2025, CVRx had 252 active implanting centers, up from 250 as of September 30, 2025 [4] - The number of sales territories in the U.S. increased to 53, adding three territories during Q4 2025 [4] Debt Facility - On January 9, 2026, the company amended its term loan agreement, increasing the facility by $50 million to a total of $100 million, with an additional $10 million borrowed at closing [11] - The amended loan has an interest rate of 9.40% or prime plus 2.65%, with an extended interest-only period [11] Clinical Development - The FDA approved the BENEFIT-HF trial design in November 2025, which aims to evaluate Barostim's impact on heart failure patients [10] - The trial is set to randomize 2,500 patients across 200 centers in the U.S. and Germany, with expected costs of $20 million to $30 million over five to seven years [10]

Core Insights - CVRx, Inc. is a commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases [3] - The management team will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. (PT) [1] - Barostim™ is the first FDA-approved medical technology using neuromodulation to alleviate heart failure symptoms [3] Company Overview - CVRx specializes in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases [3] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aimed at restoring balance to the autonomic nervous system [3] - Barostim has received FDA Breakthrough Device designation and is approved for heart failure patients in the U.S., as well as certified under EU Medical Device Regulation [3] Event Information - A live webcast of the J.P. Morgan Healthcare Conference presentation will be available at ir.cvrx.com, with an archived version accessible for a limited time [2]

Core Insights - CVRx, Inc. is a commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases [3] - The management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 [1] - The Barostim™ device is the first FDA-approved technology using neuromodulation to alleviate heart failure symptoms [3] Company Overview - CVRx specializes in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases [3] - Barostim™ is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aimed at restoring balance to the autonomic nervous system [3] - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as CE Mark approval for heart failure and resistant hypertension in the European Economic Area [3] Event Details - The fireside chat is scheduled for December 3, 2025, at 2:00 p.m. (ET) and will be available via webcast on the company's investor relations page [1][2]

Core Insights - CVRx, Inc. is a commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases [3] - The management team will present at the Jefferies Global Healthcare Conference in London on November 18, 2025 [1] - The presentation will be available via live audio webcast on the company's investor relations page [2] Company Overview - CVRx specializes in developing, manufacturing, and commercializing neuromodulation solutions, with Barostim™ being its flagship product [3] - Barostim is the first FDA-approved medical technology that uses neuromodulation to alleviate symptoms in heart failure patients [3] - The device delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system [3] - Barostim has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S. [3] - The device is also compliant with EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area [3]

Core Insights - CVRx, Inc. plans to release its third quarter 2025 financial and operating results on November 5, 2025, after market close [1] - A conference call will be held at 4:30 p.m. Eastern Time on the same day to discuss the results [1] Company Overview - CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3] - The company's flagship product, Barostim™, is the first FDA-approved medical technology that uses neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation and holding CE Mark for heart failure and resistant hypertension in the European Economic Area [3]

Core Insights - CVRx, Inc. is a commercial-stage medical device company focused on innovative neuromodulation solutions for cardiovascular diseases [3] - The company will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, at 3:00 PM Eastern Time [1] - Barostim™ is the first FDA-approved medical technology using neuromodulation to alleviate heart failure symptoms [3] Company Overview - CVRx specializes in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases [3] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aimed at restoring balance to the autonomic nervous system [3] - The device has received FDA Breakthrough Device designation and is approved for heart failure patients in the U.S., as well as certified under EU Medical Device Regulation [3] Conference Details - A live audio webcast of the conference presentation will be available on the investor relations page of the company's website [2]

Core Insights - CVRx, Inc. plans to release its second quarter 2025 financial and operating results on August 4, 2025, after market close [1] - A conference call will be held at 4:30 PM Eastern Time on the same day to discuss the results [1] Company Overview - CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3] - The company's flagship product, Barostim™, is the first FDA-approved medical technology that uses neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] - The device has received FDA Breakthrough Device designation and is approved for use in heart failure patients in the U.S., as well as being compliant with EU Medical Device Regulation and holding CE Mark for heart failure and resistant hypertension in the European Economic Area [3]

Company Overview - CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases [3] - The company's flagship product, Barostim™, is the first FDA-approved medical technology that uses neuromodulation to alleviate symptoms in heart failure patients [3] - Barostim is an implantable device that delivers electrical pulses to baroreceptors in the carotid artery, aiming to restore balance to the autonomic nervous system and reduce heart failure symptoms [3] Recent Developments - CVRx management will present at the William Blair 45 Annual Growth Stock Conference on June 4, 2025, at 10:00 am Central Time via webcast [1] - A live audio webcast of the conference presentation will be accessible on the investor relations page of the company's website [2] Regulatory Approvals - Barostim has received FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. [3] - The device has also obtained the CE Mark for heart failure and resistant hypertension in the European Economic Area [3]